

Supplementary Table S1: Summary of Treatment-Related TEAEs in Safety Analysis Set by Dose Level

	DL1 3 × 10⁷ N=3	DL2 1 × 10⁸ N=3	DL3 3 × 10⁸ N=6	DL4 9 × 10⁸ N=4	Total N=16
CAR T-cell dose					
Patients with any TEAEs related to CTX130, n (%)	1 (33.3)	2 (66.7)	5 (83.3)	4 (100.0)	12 (75.0)
General disorders and administration site conditions, n (%)	1 (33.3)	1 (33.3)	2 (33.3)	3 (75.0)	7 (43.8)
Fatigue	1 (33.3)	–	2 (33.3)	2 (50.0)	5 (31.3)
Chills	–	–	–	–	–
Pyrexia	–	1 (33.3)	–	2 (50.0)	3 (18.8)
Influenza-like illness	–	–	–	1 (25.0)	1 (6.3)
Pain	–	–	–	–	–
Immune system disorders, n (%)	–	–	4 (66.7)	4 (100.0)	8 (50.0)
Cytokine release syndrome	–	–	4 (66.7)	4 (100.0)	8 (50.0)
Skin and subcutaneous tissue disorders, n (%)	–	–	2 (33.3)	–	2 (12.5)
Hyperhidrosis	–	–	1 (16.7)	–	1 (6.3)
Rash maculo-papular	–	–	1 (16.7)	–	1 (6.3)
Alopecia	–	–	–	–	–
Pruritus	–	–	–	–	–
Blood and lymphatic system disorders, n (%)	–	–	2 (33.3)	1 (25.0)	3 (18.8)
Anemia	–	–	–	1 (25.0)	1 (6.3)
Febrile neutropenia	–	–	2 (33.3)	–	2 (12.5)
Neutropenia	–	–	–	1 (25.0)	1 (6.3)
Investigations n (%)	–	1 (33.3)	1 (16.7)	2 (50.0)	4 (25.0)
Aspartate aminotransferase increased	–	1 (33.3)	–	–	1 (6.3)
Blood creatinine increased	–	–	–	1 (25.0)	1 (6.3)
Weight decreased	–	–	1 (16.7)	1 (25.0)	2 (12.5)
Gastrointestinal disorders, n (%)	–	–	1 (16.7)	2 (50.0)	3 (18.8)
Abdominal pain	–	–	–	2 (50.0)	2 (12.5)
Diarrhea	–	–	1 (16.7)	–	1 (6.3)
Nausea	–	–	1 (16.7)	–	1 (6.3)
Stomatitis	–	–	–	–	–
Toothache	–	–	–	–	–
Infections and infestations, n (%)	–	–	–	2 (50.0)	2 (12.5)
Folliculitis	–	–	–	–	–
Mucosal infection	–	–	–	–	–

Upper respiratory tract infection	—	—	—	1 (25.0)	1 (6.3)
Urinary tract infection	—	—	—	1 (25.0)	1 (6.3)
Metabolism and nutrition disorders, n (%)	1 (33.3)	—	—	1 (25.0)	2 (12.5)
Decreased appetite	1 (33.3)	—	—	1 (25.0)	2 (12.5)
Hypokalemia	—	—	—	—	—
Respiratory, thoracic, and mediastinal disorders, n (%)	—	—	—	1 (25.0)	1 (6.3)
Dyspnea	—	—	—	1 (25.0)	1 (6.3)
Eye disorders, n (%)	1 (33.3)	—	—	—	1 (6.3)
Visual impairment	1 (33.3)	—	—	—	1 (6.3)
Musculoskeletal and connective tissue disorders, n (%)	—	—	—	1 (25.0)	1 (6.3)
Arthralgia	—	—	—	1 (25.0)	1 (6.3)
Myalgia	—	—	—	—	—
Nervous system disorders, n (%)	—	—	—	1 (25.0)	1 (6.3)
Dizziness	—	—	—	—	—
Dysgeusia	—	—	—	1 (25.0)	1 (6.3)
Hyperesthesia	—	—	—	—	—
Vascular disorders, n (%)	—	—	—	—	—
Hypotension	—	—	—	—	—

CAR, chimeric antigen receptor; DL, dose level; TEAE, treatment-emergent adverse event.